



RECEIVED
SEP 09 2003
TECH CENTER

PATENT
Customer No. 22,852
Attorney Docket No. 06478.1465-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Claude NÉGRIER et al.) Group Art Unit: 1653
)
Application No.: 10/067,894) Examiner: Holly G. Schnizer
)
Filed: February 8, 2002)
)
For: MODIFIED FACTOR VIII cDNA AND ITS USE)
FOR THE PRODUCTION OF FACTOR VIII)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

09/08/2003 BABRAHA1 00000052 10067894

02 FC:1806

180.00 0P

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 5, 2003

By: 
Sanya Sukduang
Reg. No. 46,390

583911_1



INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

Atty. Dock. No.	178.1465-00	Appln. No.	10/067,894
Applicant	Claude Négrier et al.		
Filing Date	February 8, 2002	Group:	1653

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
EP 1231220 A1	08/14/2002	Europe			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Hoeben et al., "Expression of the Blood-Clotting Factor-VIII cDNA Is Repressed by a Transcriptional Silencer Located in Its Coding Region," <i>Blood</i> , 85:2447-2454 (1995).
Toole et al., "A Large Region (\approx 95 kDa) of Human Factor VIII is Dispensable for <i>in vitro</i> Procoagulant Activity," <i>Proc. Natl. Acad. Sci. USA</i> , 83:5939-5942 (1986).

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.